Advances in our understanding of the pathophysiology, detection and management of cerebral amyloid angiopathy

European Neurological Review

Volumn 7, Issue 2, 2012, Pages 134-139

  Pontes Neto, Octavio M ^a,b   Auriel, Eitan ^a,b   Greenberg, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amyloid; Amyloid angiopathy; Cognitive decline; Intracerebral haemorrhage; Stroke

Indexed keywords

EID: 84865494530     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2012.07.02.134     Document Type: Article

References (105)

1. Okazaki H, Reagan TJ, Campbell RJ, Clinicopathologic studies of primary cerebral amyloid angiopathy, Mayo Clin Proc, 1979;54:22-31.
2. Oppenheim G, Über "drusige Nekrosen" in der Grosshirnrinde, Neurol Centralbl, 1909;28:410-3.
3. Vinters HV, Cerebral amyloid angiopathy, A critical review, Stroke, 1987;18:311-24.
4. Greenberg SM, Vonsattel JP, Stakes JW, et al., The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage, Neurology, 1993;43(10):2073-9.
5. Neuropathology Group, Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS), Lancet, 2001;357(9251):169-75.
6. Pfeifer LA, White LR, Ross GW, et al., Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study, Neurology, 2002;58(11):1629-34.
7. Palsdottir A, Snorradottir AO, Thorsteinsson L, Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects, Brain Pathol, 2006;16(1):55-9.
8. Greenberg SM, Vonsattel JP, Diagnosis of cerebral amyloid angiopathy, sensitivity and specificity of cortical biopsy, Stroke, 1997;28:1418-22.
9. Scharf J, Brauherr E, Forsting M, Sartor K, Significance of haemorrhagic lacunes on MRI in patients with hypertensive cerebrovascular disease and intracerebral haemorrhage, Neuroradiology, 1994;36:504-8.
10. Offenbacher H, Fazekas F, Schmidt R, et al., MR of cerebral abnormalities concomitant with primary intracerebral hematomas, Am J Neuroradiol, 1996;17:573-8.
11. Fazekas F, Kleinert R, Roob G, et al., Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds, Am J Neuroradiol, 1999;20:637-42.
12. Greenberg SM, Vernooij MW, Cordonnier C, et al., Cerebral microbleeds: a guide to detection and interpretation, Lancet Neurol, 2009;8(2):165-74.
13. Knudsen KA, Rosand J, Karluk D, Greenberg SM, Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria, Neurology, 2001;56:537-9.
14. Auriel E, Greenberg SM, The pathophysiology and clinical presentation of cerebral amyloid angiopathy, Curr Atheroscler Rep, 2012;14(4):343-50.
15. Johnson KA, Gregas M, Becker JA, et al., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy, Ann Neurol, 2007;62(3):229-34.
16. Goldgaber D, Lerman MI, McBride OW, et al., Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease, Science, 1987;235:877-80.
17. Haass C, Schlossmacher MG, Hung AY, et al., Amyloid beta-peptide is produced by cultured cells during normal metabolism, Nature, 1992;359:322-5.
18. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM, Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides, Proc Natl Acad Sci U S A, 1987;84:4190-4.
19. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA, Generation of beta- amyloid in the secretory pathway in neuronal and nonneuronal cells, Proc Natl Acad Sci U S A, 1993;90:2092-6.
20. Rostagno A, Lal R, Ghiso J, Protein misfolding, aggregation, and fibril formation: common features of cerebral and non-cerebral amyloid diseases. In: Dawbarn D, Allen S (eds), The Neurobiology of Alzheimer's Disease, Oxford: Oxford University Press, 2007;133-60.
21. Hartz AM, Bauer B, Soldner EL, et al., Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy, Stroke, 2012;43:514-23.
22. Herzig MC, Van Nostrand WE, Jucker M, Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models, Brain Pathol, 2006;16(1):40-54.
23. Fukuchi K, Ho L, Younkin SG, et al., High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice, Am J Pathol, 1996;149(1):219-27.
24. Burgermeister P, Calhoun ME, Winkler DT, Jucker M, Mechanisms of cerebrovascular amyloid deposition. Lessons from mouse models, Ann N Y Acad Sci, 2000;903:307-16.
25. Eisele YS, Obermüller U, Heilbronner G, et al., Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis, Science, 2010;330:980-2.
26. Garcia-Alloza M, Gregory J, Kuchibhotla KV, et al., Cerebrovascular lesions induce transient β-amyloid deposition, Brain, 2011;134:3697-707.
27. Vinters HV, Wang ZZ, Secor DL, Brain parenchymal and microvascular amyloid in Alzheimer's disease, Brain Pathol, 1996;6:179-95.
28. Winkler DT, Bondolfi L, Herzig MC, et al., Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy, J Neurosci, 2001;21:1619-27.
29. Greenberg SM, Nandigam RN, Delgado P, et al., Microbleeds versus macrobleeds: evidence for distinct entities, Stroke, 2009;40(7):2382-6.
30. Mandybur TI, Cerebral amyloid angiopathy: the vascular pathology and complications, J Neuropathol Exp Neurol, 1986;45(1):79-90.
31. Vonsattel JP, Myers RH, Hedley-Whyte ET, et al., Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study, Ann Neurol, 1991;30:637-49.
32. Revesz T, Ghiso J, Lashley T, et al., Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view, J Neuropathol Exp Neurol, 2003;62:885-98.
33. Fisher CM, Pathological observations in hypertensive cerebral hemorrhage, J Neuropathol Exp Neurol, 1971;30:536-50.
34. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study (MRC CFAS), Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales, Lancet, 2001;357:169-75.
35. Jellinger KA, Alzheimer disease and cerebrovascular pathology: an update, J Neural Transm, 2002;109:813-36.
36. Ellis RJ, Olichney JM, Thal LJ, et al., Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV, Neurology, 1996;46:1592-6.
37. Sudlow C, Martínez González NA, Kim J, Clark C, Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and metaanalyses of 31 studies among 5961 cases and 17,965 controls, Stroke, 2006;37:364-70.
38. Nicoll JA, Burnett C, Love S, et al., High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy, Ann Neurol, 1997;41:716-21.
39. Farrer LA, Cupples LA, Haines JL, et al., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis, APOE and Alzheimer Disease Meta Analysis Consortium, JAMA, 1997;278:1349-56.
40. Holtzman DM, Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy, J Mol Neurosci, 2001;17:147-55.
41. Greenberg SM, Vonsattel JP, Segal AZ, et al., Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy, Neurology, 1998;50:961-5.
42. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM, Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels, J Neuropathol Exp Neurol, 1998;57:353-9.
43. Brouwers HB, Biffi A, Ayres AM, et al., Apolipoprotein E genotype predicts hematoma expansion in lobar intracerebral hemorrhage, Stroke, 2012;43(6):1490-5.
44. Brouwers HB, Biffi A, McNamara KA, et al., Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage, Stroke, 2012;(epub ahead of print)
45. Biffi A, Shulman JM, Jagiella JM, et al., Genetic variation at CR1 increases risk of cerebral amyloid angiopathy, Neurology, 2012;78:334-41.
46. Viswanathan A, Greenberg SM, Chapter 38: Intracerebral hemorrhage, Handb Clin Neurol, 2008;93:767-90.
47. Raposo N, Viguier A, Cuvinciuc V, et al., Cortical subarachnoid haemorrhage in the elderly: a recurrent event probably related to cerebral amyloid angiopathy, Eur J Neurol, 2011;18:597-603.
48. Thomas T, Thomas G, McLendon C, et al., beta-Amyloidmediated vasoactivity and vascular endothelial damage, Nature, 1996;380:168-71.
49. Christie R, Yamada M, Moskowitz M, Hyman B, Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy, Am J Pathol. 2001;158:1065-71.
50. Smith EE, Vijayappa M, Lima F, et al., Impaired visual evoked flow velocity response in cerebral amyloid angiopathy, Neurology, 2008;71:1424-30.
51. Smith EE, Gurol ME, Eng JA, et al., White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage, Neurology, 2004;63:1606-12.
52. Dumas A, Dierksen GA, Gurol ME, et al., Functional MRI detection of vascular reactivity in cerebral amyloid angiopathy, Ann Neurol, 2012;(epub ahead of print).
53. Arvanitakis Z, Leurgans SE, Wang Z, et al., Cerebral amyloid angiopathy pathology and cognitive domains in older persons, Ann Neurol, 2011;69:320-7.
54. Fountain NB, Eberhard DA, Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature, Neurology, 1996;46:190-7.
55. Eng JA, Frosch MP, Choi K, et al., Clinical manifestations of cerebral amyloid angiopathy-related inflammation, Ann Neurol, 2004;55:250-6.
56. Kinnecom C, Lev MH, Wendell L, et al., Course of cerebral amyloid angiopathy-related inflammation, Neurology, 2007;68:1411-6.
57. Puchtler H, Waldrop FS, Meloan SN, A review of light, polarization and fluorescence microscopic methods for amyloid, Appl Pathol, 1985;3:5-17.
58. Ripoll MA, Siosteen B, Hartman M, Raininko R, MR detectability and appearance of small experimental intracranial hematomas at 1.5 T and 0.5 T. A 6-7-month follow-up study, Acta Radiol, 2003;44:199-205.
59. Alemany Ripoll M, Stenborg A, Sonninen P, et al., Detection and appearance of intraparenchymal haematomas of the brain at 1.5 T with spin-echo, FLAIR and GE sequences: poor relationship to the age of the haematoma, Neuroradiology, 2004;46:435-43.
60. Haacke EM, DelProposto ZS, Chaturvedi S, et al., Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging, Am J Neuroradiol, 2007;28:316-7.
61. Nandigam RN, Viswanathan A, Delgado P, et al., MR imaging detection of cerebral microbleeds: effect of susceptibilityweighted imaging, section thickness, and field strength, Am J Neuroradiol, 2009;30(2):338-43.
62. Greenberg SM, Eng JA, Ning M, et al., Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage, Stroke, 2004;35(6):1415-20.
63. Feldman HH, Maia LF, Mackenzie IR, et al., Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer disease, Stroke, 2008;39(10):2894-7.
64. Linn J, Halpin A, Demaerel P, et al., Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy, Neurology, 2010;74(17):1346-50.
65. Kumar S, Goddeau RP Jr, Selim MH, et al., Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies, Neurology, 2010;74(11):893-9.
66. Linn J, Brückmann H, Superficial siderosis in cerebral amyloid angiopathy, Am J Neuroradiol, 2010;31(2):E29.
67. Vernooij MW, Ikram MA, Hofman A, et al., Superficial siderosis in the general population, Neurology, 2009;73(3):202-5.
68. Von sattel JP, Myers RH, Hedley-Whyte ET, et al., Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study, Ann Neurol, 1991;30:637-49.
69. Klunk WE, Engler H, Nordberg A, et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B, Ann Neurol, 2004;55:306-19.
70. Bacskai BJ, Hickey GA, Skoch J, et al., Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice, Proc Natl Acad Sci, 2003;100:12462-7.
71. Bacskai BJ, Frosch MP, Freeman SH, et al., Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report, Arch Neurol, 2007;64:431-4.
72. Ly JV, Donnan GA, Villemagne VL, et al., 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage, Neurology, 2010;74:487-93.
73. Greenberg SM, Grabowski T, Gurol ME, et al., Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B, Ann Neurol, 2008;64(5):587-91.
74. Fleisher AS, Chen K, Liu X, Roontiva A, et al., Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease, Arch Neurol, 2011;68(11):1404-11.
75. De Meyer G, Shapiro F, Vanderstichele H, et al., Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people, Arch Neurol, 2010;67:949-56.
76. Vemuri P, Wiste HJ, Weigand SD, et al., Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease, Ann Neurol, 2010;67:308-16.
77. Vemuri P, Wiste HJ, Weigand SD, et al., Serial MRI and CSF biomarkers in normal aging, MCI, and AD, Neurology, 2010;75:143-51.
78. Dubois B, Feldman HH, Jacova C, et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 2007;6:734-46.
79. de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM, Current state and future directions of neurochemical biomarkers for Alzheimer's disease, Clin Chem Lab Med, 2007;45:1421-34.
80. Hulstaert F, Blennow K, Ivanoiu A, et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, 1999;52:1555-62.
81. Verbeek MM, De Jong D, Kremer HP, Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases, Ann Clin Biochem, 2003;40:25-40.
82. Sunderland T, Linker G, Mirza N, et al., Decreased betaamyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, 2003;289:2094-103.
83. Verbeek MM, Kremer BP, Rikkert MO, et al., Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy, Ann Neurol, 2009;66:245-49.
84. Eckman MH, Rosand J, Knudsen KA, et al., Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis, Stroke, 2003;34:1710-6.
85. Lee SH, Ryu WS, Roh JK, Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage, Neurology, 2009;72:171-6.
86. Soo YO, Yang SR, Lam WW, et al., Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds, J Neurol, 2008;255:1679-86.
87. Biffi A, Halpin A, Towfighi A, et al., Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy, Neurology, 2010;75:693-8.
88. Arima H, Tzourio C, Anderson C, et al., PROGRESS Collaborative Group, Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial, Stroke, 2010;41:394-6.
89. Chapman N, Huxley R, Anderson C, et al., Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial, Stroke, 2004;35:116-21.
90. Morgenstern LB, Hemphill JC III, Anderson C, et al., Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 2010;41:2108-29.
91. Mendelow AD, Gregson BA, Fernandes HM, et al., Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomized trial, Lancet, 2005:365:387-97.
92. Mendelow AD, Gregson BA, Mitchell PM, et al, Surgical trial in lobar intracerebral haemorrhage (STICH II) protocol, Trials, 2011;12:124.
93. Mehndiratta P, Manjila S, Ostergard T, et al., Cerebral amyloid angiopathy-associated intracerebral hemorrhage: pathology and management, Neurosurg Focus, 2012;32(4):E7.
94. Kloppenborg RP, Richard E, Sprengers ME, et al., Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment, J Neuroinflammation, 2010;7:18.
95. Luppe S, Betmouni S, Scolding N, Wilkins A, Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine, J Neurol, 2010;257:2103-5.
96. DiFrancesco JC, Brioschi M, Brighina L, et al., Anti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: a case report, Neurology, 2011;76:842-4.
97. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM, Warfarin associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study, Neurology, 2000;55:947-51.
98. Maia LF, Mackenzie IR, Feldman HH, Clinical phenotypes of cerebral amyloid angiopathy, J Neurol Sci, 2007;257:23-30.
99. Eckman MH, Wong LK, Soo YO, et al., Patient-specific decisionmaking for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?, Stroke, 2008;39:3308-15.
100. Palsdottir A, Snorradottir AO, Thorsteinsson L, Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects, Brain Pathol, 2006;16:55-9.
101. Roks G, Van Harskamp F, De Koning I, et al., Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692), Brain, 2000;123:2130-40.
102. Vidal R, Frangione B, Rostagno A, et al., A stop-codon mutation in the BRI gene associated with familial British dementia, Nature, 1999;399:776-81.
103. Vidal R, Garzuly F, Budka H, et al., Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G), Am J Pathol, 1996;148:361-6.
104. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, et al., The cerebral beta-amyloid angiopathies: hereditary and sporadic, Brain Pathol, 2006;16:30-9.
105. Greenberg SM, Shin Y, Grabowski TJ, et al., Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation, Neurology, 2003;60:1020-2.